Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Accounts Payables for 10 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 39.56% to $21.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, up 39.56% year-over-year, with the annual reading at $21.2 million for FY2025, 39.56% up from the prior year.
  • Accounts Payables for Q4 2025 was $21.2 million at Akebia Therapeutics, up from $10.1 million in the prior quarter.
  • The five-year high for Accounts Payables was $42.0 million in Q2 2021, with the low at $9.0 million in Q3 2023.
  • Average Accounts Payables over 5 years is $18.6 million, with a median of $14.9 million recorded in 2023.
  • The sharpest move saw Accounts Payables tumbled 54.14% in 2023, then soared 49.3% in 2024.
  • Over 5 years, Accounts Payables stood at $33.6 million in 2021, then crashed by 46.35% to $18.0 million in 2022, then dropped by 18.79% to $14.6 million in 2023, then grew by 3.72% to $15.2 million in 2024, then skyrocketed by 39.56% to $21.2 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $21.2 million, $10.1 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.